Nowadays, anti-PD-1/PD-L1 therapy is effectively used in the treatment of, amongst others, non-small cell lung cancer, classical Hodgkin lymphoma, melanoma, and renal cell carcinoma [48]. This evidence concerns the gene CD274 and classic Hodgkin lymphoma.